Pomerantz Law Firm Investigating Claims Against Organogenesis Holdings: What Investors Should Know

Investor Alert: Pomerantz LLP Investigates Organogenesis Holdings

The renowned Pomerantz Law Firm has recently initiated an investigation into potential claims concerning Organogenesis Holdings Inc. (NASDAQ: ORGO). This scrutiny arises amidst troubling developments regarding the company's recent clinical trials and stock performance.

On September 25, 2025, Organogenesis made headlines with a press release indicating that its second Phase 3 trial of the cryopreserved amniotic suspension allograft, ReNu, failed to achieve the primary endpoint aimed at significantly reducing pain levels. This disappointing news prompted a sharp decline in Organogenesis' stock price, which dropped $0.58 per share, or 12.39%, resulting in a closing price of $4.10 on September 26, 2025.

The investigation led by Pomerantz LLP seeks to determine whether there have been any unlawful business practices or instances of securities fraud perpetrated by Organogenesis or among its executives and directors. Investors who may have been impacted are encouraged to reach out to Danielle Peyton at Pomerantz LLP for further information and potential participation in any class action proceedings.

Key Developments Surrounding Organogenesis

Organogenesis Holdings focuses on regenerative medicine and advanced wound care. The company has faced increasing scrutiny, especially with its product, ReNu, which is intended for enhancing surgical outcomes in orthopedic procedures. Following the announcement of the trial's failure, the company's Chief Operating Officer, Patrick Bilbo, indicated plans to meet with the U.S. Food and Drug Administration (FDA) by the end of October to discuss a potential submission pathway for the Biologics License Application (BLA). This meeting is critical as it will explore the possibility of leveraging combined efficacy data from both Phase 3 studies to support their application for approval.

The Role of Pomerantz LLP

Pomerantz LLP has built a formidable reputation as a leader in the realm of corporate, securities, and antitrust litigation. Established over 85 years ago by Abraham L. Pomerantz, the firm has always taken an aggressive stand in safeguarding the rights of investors and shareholders. The firm is well-known for its successful track record in recovering significant damages for clients affected by corporate misconduct.

As this investigation unfolds, Pomerantz aims to not only bring to light any potential wrongdoings but also to assist shareholders in navigating the complexities of securities litigation. Investors wishing to stay informed or consider their options should definitely stay engaged with ongoing developments regarding Organogenesis.

Conclusion

The challenges facing Organogenesis Holdings serve as a crucial reminder to investors about the volatility present in the biotech sector. With Pomerantz LLP now involved in investigating these claims, it is essential for those affected to seek legal counsel and stay updated on the situation. As more information becomes available, stakeholders should remain vigilant in their assessments and responses to the unfolding events. For any investor who has suffered losses due to possible fraud or misconduct at Organogenesis, joining forces with Pomerantz could be a significant step towards reclaiming their investment rights.